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Abstract
Background: Alzheimer’s disease (AD) is the most common form of neurodegenerative disorder that leads to a
decline in cognitive function. In AD, aggregates of amyloid β peptide precede the accumulation of neurofibrillary
tangles, both of which are hallmarks of the disease. The great majority (>90 %) of the AD cases are not originated
from genetic defects, therefore supporting the central roles of epigenetic modifications that are acquired progressively
during the life span. Strong evidences have indicated the implication of epigenetic modifications, including histone
modification and DNA methylation, in AD. Recent studies revealed that 5-hydroxymethylcytosine (5hmC) is
dynamically regulated during neurodevelopment and aging.
Results: We show that amyloid peptide 1–42 (Aβ1-42) could significantly reduce the overall level of 5hmC in vitro. We
found that the level of 5hmC displayed differential response to the pathogenesis in different brain regions, including
the cortex, cerebellum, and hippocampus of APP-PSEN1 double transgenic (DTg) mice. We observed a significant
decrease of overall 5hmC in hippocampus, but not in cortex and cerebellum, as the DTg mice aged. Genome-wide
profiling identified differential hydroxymethylation regions (DhMRs) in DTg mice, which are highly enriched in introns,
exons and intergenic regions. Gene ontology analyses indicated that DhMR-associated genes are highly enriched in
multiple signaling pathways involving neuronal development/differentiation and neuronal function/survival.
Conclusions: 5hmC-mediated epigenetic regulation could potentially be involved in the pathogenesis of AD.
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Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease involving multiple pathologic processes and is
characterized by the deposition of amyloid beta (Aβ) pep-
tide, neurofibrillary tangles (NFTs) composed of hyperpho-
sphorylated protein tau, and neuronal cell death [1, 2].
Recent studies indicate that epigenetic pathways could be
involved in the pathogenesis of AD [3, 4]. DNA methyla-
tion (5-methylcytosine, 5mC) plays important roles in
regulating gene expression and is involved in multiple neu-
rodevelopmental and neurodegenerative disorders [5–7].
Changes in 5mC at the global level or at specific loci are
seen in the brain tissues of AD model mice, as well as AD
patients [4, 8–12]. Although some regions and loci show
hypermethylation [13], global DNA hypomethylation has
been observed in the entorhinal cortex of some AD patients
[14], suggesting DNA methylation is differentially affected
in a region- and loci-specific manner. Previous studies also
found that the promoter regions of amyloid precursor
protein (APP) and presenilin 1 (PSEN1) displayed age-
dependent hypomethylation [10, 15–17]. Furthermore, in
vitro hypomethylation of PSEN1 increased the cleavage of
APP and the production of Aβ in a neuroblastoma cell line
[18]. Recently, two large-scale epigenome-wide association
studies uncovered the alteration of site-specific methylation
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in the brains of AD patients [11, 12]. These results imply
DNA methylation could play important roles in the patho-
genesis of AD.
Recently, another cytosine modification, 5-hydroxy
methylcytosine (5hmC), was identified and found to be
highly abundant in the neuronal system [19–21]. Ten-
eleven translocation (Tet) family proteins, including
Tet1, Tet2, and Tet3, are known to catalyze the hydrox-
ylation of 5mC to 5hmC [19, 22–24]. Recent studies
strongly indicate that 5hmC not only serves as an inter-
mediate of DNA demethylation, but can also perform
as a stable epigenetic marker. 5hmC is ~10-fold more
enriched in neurons than other cell types, and it is ac-
quired globally and exhibits dynamic features and
region-specific patterns during postnatal development
and aging of the neuronal system [20, 25, 26]. Genome-
wide studies reveal that 5hmC can be enriched in dis-
tinct genomic regions, such as gene bodies, promoters,
and distal regulatory regions [27–29], and the enrich-
ment of 5hmC ate gene bodies could be positively
correlated with transcriptional level, which might be
achieved via interaction with histone modifications
[30–34]. The alteration of global 5hmC and differen-
tially hydroxymethylated regions (DhMRs) are seen in
several neurodevelopmental diseases, including Rett
syndrome, autism, and neurodegenerative diseases like
Huntington’s disease and fragile X-associated tremor/
ataxia syndrome (FXTAS), suggesting 5hmC could play
important roles in neurological diseases [20, 25, 35–37].
Despite the clear alteration of DNA methylation ob-
served in AD, whether and how 5hmC is involved in AD
pathogenesis still remain largely unknown. Using an im-
munostaining method, Condliffe et al. found a significant
decrease of global 5hmC in the cortex and cerebellum of
AD patients [38]. In contrast, using the same technique,
other studies reported an increase of global 5hmC in both
AD mouse model and patients samples [39–41]. To study
the alteration of 5hmC in AD and explore the potential
role(s) of 5hmC-mediated epigenetic regulation in the
pathogenesis of AD, here we investigated the effect of Aβ
on 5hmC in vitro and found Aβ treatment could signifi-
cantly decrease the level of 5hmC in a dose-dependent
pattern. Furthermore, we found that 5hmC levels dis-
played an age-dependent decrease in the hippocampus,
but not in the cortex and cerebellum, of APP-PSEN1
double-transgenic (DTg) mice. Using a chemical-labeling
5hmC enrichment approach, we performed genome-wide
profiling of 5hmC. We found that, although AD pathogen-
esis did not change the overall distribution of 5hmC, there
were differentially hydroxymethylated regions (DhMRs)
in DTg mice. The DhMRs identified are involved in a
number of neuronal signaling pathways, indicating a
5hmC-mediated epigenetic pathway could potentially
play important roles in the pathogenesis of AD.
Results
Aβ reduces the global level of 5-hydroxymethylcytosine
in vitro
Aβ deposition is one of the hallmarks of AD pathogen-
esis, and is known to induce neuronal cell death and
other neuronal pathogenic outcomes. To study the roles
of 5-hydroxymethylcytosine (5hmC)-mediated epigenetic
modification in AD pathogenesis, we first studied the ef-
fect of Aβ(1–42), a toxic form of peptide associated with
AD, on the level of 5hmC with cultured cells. After be-
ing treated with Aβ peptide for 48 h, the overall level of
5hmC in HEK293ft cells decreased, and Aβ peptide at a
1-μM concentration was the most effective dose
(Fig. 1a-b). To ensure equal spotting of total DNA on
the membrane, the same blot was then stained with
0.02 % methylene blue (Additional file 1: Figure S1).
Considering cognitive function is severely impaired
and the roles of adult neurogenesis in learning and
memory, we further tested the effect of Aβ peptide on
5hmC levels in adult neural stem cells (aNSCs). ANSCs
harbors in specific regions, subventricular zone of lateral
ventricle and subgranular zone of dentate gyrus of adult
mammalian brain, and is involved in neurological disor-
ders including AD. The isolated aNSCs were positive for
neural stem cell markers Nestin and Sox2 (Fig. 1c-f).
After treated with Aβ peptide at a 1-μM concentration
for 48 h, the level of 5hmC was also significantly de-
creased in the cultured aNSCs (Fig. 1g-h). We also com-
pared the overall level of 5hmC in HEK293ft cells,
aNSCs and neuronal tissues. We found that 5hmC level
was significantly higher in neuronal tissues than in
HEK293ft and aNSCs cells, which both are capable of
proliferation (Fig. i-j). Taken together, these results indi-
cate that Aβ peptide could significantly affect the level
of 5hmC in multiple cultured cells.
5-hydroxymethylcytosine level decreases during aging in
an AD mouse model
Previous studies have indicated that 5hmC could be ac-
quired in the brain during postnatal development and
aging [20, 25]. To examine whether the level of 5hmC is
affected during AD pathogenesis, we dissected multiple
brain regions, including cortex, cerebellum, and hippo-
campus from 12-week-old (adult) and 67-week-old
(aged) wild-type (WT) and APP-PSEN1 double trans-
genic (DTg) mice. Consistent with our previous study
[20], from 12 weeks to 67 weeks, 5hmC exhibits no or
slight acquisition in the cortex and cerebellum of both
WT and DTg mice (Fig. 2b, e, h). Quantification results
showed no significant difference of these brain two re-
gions between WT and DTg mice (Fig. 2a, b, d, e, g, h).
In hippocampus, there is no significant change in 5hmC
in WT mice during aging; however, at the 67-week time
point, the 5hmC level of DTg mice hippocampus
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decreased significantly compared to age-matched WT
control (Fig. 2c, f, i). Collectively, these results indicate
that the global level of 5hmC is affected in specific brain
regions during AD pathogenesis.
Acquisition of 5hmC on gene bodies is altered in aged
AD mice
To explore whether the distribution features of 5hmC in
the genome are altered during AD pathogenesis, we
employed a previously established 5hmC chemical label-
ing and affinity purification method [26] and performed
5hmC genome-wide profiling. Based on dot-blot results,
our subsequent study focused on hippocampus. To per-
form genome-wide sequencing of 5hmC, hippocampus
tissues were dissected from three adult (12-week) DTg
mice and three littermate WT mice; at the 67-week time
point (aged), hippocampus tissues were dissected from
two DTg mice and two WT littermate mice. Through
deep-sequencing, 11–23 million total reads and around
9–18 million monoclonal reads were generated from
each sample (Additional file 2: Table S1). Sequence data
were analyzed using our established pipeline [20], and
Fig. 1 The effects of Aβ(1–42) peptide on 5hmC level in vitro. a-b Dot-blot assay shows Aβ treatment significantly decreased total 5hmC levels in
a dose-dependent manner in HEK293ft cells. Aβ at 1-μM concentration is the most effective at decreasing 5hmC levels (*p < 0.05;** p < 0.01,
unpaired t-test). c-f The cultured aNSCs are positive for neural stem cell markers Nestin (d) and SOX2 (e). g The representative images of dot-blot
assay of Aβ treatment on 5hmC level in aNSCs. h The quantification result indicates Aβ at 1-μM concentration significantly decreases 5hmC level
in aNSCs (*p < 0.05;** p < 0.01, unpaired t-test). i-j Dot-blot assay indicates that the global level of 5hmC in cortex is significantly higher than in
HEK293ft cells and aNSCs (*p < 0.05;** p < 0.01, unpaired t-test)
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peaks were identified by MACS software [42]. 6115 and
8335 5hmC peaks were called from adult WT and DTg
mice, respectively (Fig. 3a, b). At the 67-week time point,
39,606 and 19,977 peaks were identified from WT and
DTg mice, respectively (Fig. 3a, b). Although during the
aging process, AD pathogenesis did not significantly
affect the shared peaks between adult and aged mice of
each genotype: 5518 peaks were shared between adult
and aged WT mice, and 5289 peaks were shared be-
tween adult and aged DTg mice, the number of total
peaks decreased remarkably in aged DTg mice compared
to WT littermates. (Fig. 3a, b). At the chromosome level,
there was no visible difference between WT and DTg
mice (Additional file 1: Figure S2). Consistent with our
previous work [20], depletion of 5hmC on the X
chromosome was also observed in both WT and DTg
mice (Additional file 1: Figure S2).
We next determined the distribution of 5hmC on dis-
tinct genomic regions. Genome-wide 5hmC read density
was detected in the DTg mouse model (Fig. 3c, d). At the
12-week point, we saw no significant difference between
WT and DTg mice (Fig. 3c). However, until the 67-week
point, the shifted entire plot pattern suggested that WT
bins had more 5hmC reads (Fig. 3d). Furthermore, the
distribution of 5hmC was studied at 2.5 kb up- and down-
stream of transcription end sites (TESs), transcription
starting sites (TSSs), gene bodies, and CpG islands by ngs-
plot software (Fig. 3e-h). We found that the distribution of
5hmC showed no observable differences on TESs and
CpG islands between WT and DTg mice (Fig. 3e, h),
whereas it was slightly increased on TSSs in WT mice
compared to age-matched DTg mice (Fig. 3f). From the
12-week to 67-week time point, 5hmC was acquired on
gene bodies in both WT and DTg mice (Fig. 3g), however,
at 12- and 67-week time points, the enrichment of 5hmC
in gene bodies showed a significant decrease in DTg mice
compared to age-matched WT mice (t-test, p < 0.0001),
suggesting the acquisition of 5hmC in gene bodies was
inhibited during AD pathogenesis.
Differential hydroxymethylated regions (DhMRs)
associated with AD
The partial overlapping of 5hmC peaks in WT and
transgenic mice suggested differential hydroxymethyla-
tion. We next sought to identify differential hydroxy-
methylation regions (DhMRs) in the genome. Compared
to age-matched WT mice, 5324 and 4975 specific
DhMRs were identified in adult and aged DTg mice,
Fig. 2 Reduced 5hmC level at specific brain regions in a mouse model of AD. a-f Representative images of 5hmC dot-blot assay of 12- and 67-
week-old WT and DTg mice cortex (a, d. n = 3), cerebellum (b, e. n = 3), and hippocampus (c, f. n = 3). g-i The quantitative results indicated that
the global levels of 5hmC did not show significant difference in cortex and cerebellum of WT and DTg mice (g, h). In hippocampus, the overall
abundance of 5hmC was significantly decreased in DTg mice compared to WT mice at 67-week stage while it did not show observable difference
between WT and DTg mice at 12-week stage (i). (ANOVA post Bonferroni’s Multiple Comparison Test, mean ± s.e.m. *p < 0.05, **p < 0.01)
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Fig. 3 (See legend on next page.)
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respectively (Fig. 4a). Among them, 244 specific DhMRs
were shared between adult and aged DTg mice, which
did not appear in either adult or aged WT mice (Fig. 4a).
The DhMRs identified in adult and aged DTg mice dis-
played similar distribution trend: abundantly enriching
in intron, exon and intergenic regions (Fig. 4b), suggest-
ing a high conservation during AD progress.
To further reveal the biological function of identified
DhMRs in both adult and aged DTg mice, the genes associ-
ated with these DhMRs were extracted for enrichment ana-
lysis. We found 167 genes associating with the identified
DTg-specific DhMRs (Additional file 3: Table S2). DhMR-
associated genes were highly enriched in multiple signaling
pathways, such as the Wnt and ErbB pathways, which play
important roles in the neuronal system (Fig. 4c). Further-
more, we generated 4557 aged DTg mice-specific peaks,
and extracted 2424 genes, which associated with those
peaks (Additional file 4: Table S3). Gene Ontology assay
showed that those genes significantly enriched in some
pathways, such as Alzheimer’s disease pathway, Wnt signal-
ling, etc. (Fig. 4d). Taken together, these results suggest that
the specific enrichment of 5hmC could play some role(s) in
(See figure on previous page.)
Fig. 3 Genomic features of 5hmC peaks in hippocampus between WT and DTg mice. a-b 6115, 39,606, 8335, and 19,977 of 5hmC peaks were
called from 12- and 67-week-old WT and age-matched DTg mice biological replicates, respectively. 5518 peaks overlapped between 12- and 67-
week-old WT mice. 5289 peaks overlapped between 12- and 67-week-old DTg mice. 3011 peaks overlapped between 12-week-old WT and DTg
mice. 15,002 peaks overlapped between 67-week-old WT and DTg mice. c Genome-wide 5hmC reads were counted within each 10-kb bin in WT_12
WK and DTg_12WK mice genome. 5hmC levels were not significantly different between adult WT and DTg mice. d Genome-wide 5hmC reads
densities were higher in WT mice than in DTg mice. e, f, g and h Normalized 5hmC read densities on transcription end sites (TESs), transcription start
sites (TSSs), gene bodies, and CpG islands. The enrichment of 5hmC significantly decreased in adult and aged DTg mice compared to age matched
WT mice, but no significant difference was observed at TSS, TES, and CpG islands. t-test, p < 0.01
Fig. 4 Identification and characterization of DhMRs in AD mouse model. a Compared to age-matched WT mice, 5324 and 4975 DhMRs were identified
from adult and aged DTg-specific mice, respectively. 244 specific DhMRs were shared between adult and aged DTg mice, which did not exist either in
adult or aged WT mice. b The distribution features of DhMRs identified in adult and aged DTg mice, respectively. DhMRs highly enrich in introns, exons
and intergenic regions. Pearson’s Chi-squared test with Yates’ continuity correction was performed using their absolute mapped reads inside and outside
of each genomic feature. P-values for these tests were significant (<2.2e-16). c KEGG assay shows DhMR-associated genes are significantly enriched in
multiple neuronal signaling pathways. d KEGG assay indicates aged mice specific DhMRs-associated genes are also significantly enriched in multiple
pathways, including Alzheimer’s disease
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regulating the expression of genes related neuronal func-
tion, and involve in the pathogenesis of Alzheimer’s disease.
Two recent large-scale studies identified alterations of
DNA methylation in some loci of AD patients [11, 12],
suggesting DNA demethylation might be involved in this
process. An IGV image showed the overall reduction of
5hmC peaks in aged DTg mice compared to age
matched WT mice (Fig. 5a). Interestingly, in DTg mice
specific and aged DTg mice specific peaks associated
genes identified in our current study, two genes are also
found in the two EWAS AD studies: Ank1, Cdh23
(Fig. 5b, c). We next examined the 5hmC distribution
profile of the genes identified in those two EWAS stud-
ies, and we found the enrichment of 5hmC peaks in
some regions of those genes decreased (Additional file 1:
Figure S3). These data suggest DNA methylation is al-
tered in AD associated loci, and the potential roles of
DNA demethylation in the pathogenesis of AD.
Previous studies also noted that the enrichment of
5hmC in gene bodies might be positively correlated with
gene expression [37]. In our AD model mice, two AD-
associated genes, APP and PSEN1, were over-expressed.
We found 5hmC peaks highly enriched in APP gene bod-
ies, especially in exons, in both adult and aged DTg mice
compared to WT mice (Fig. 5d, over two-fold difference,
p < 1x10−5). It is of interest to note that we did not see sig-
nificant difference of 5hmC distribution in PSEN1. These
data indicated that 5hmC enrichment could be one of the
mechanisms promoting gene expression.
Discussion
In the present study, we performed in vitro and in vivo
studies to characterize the alterations of 5hmC-mediated
DNA demethylation in a mouse model of AD. We found
the overall level of 5hmC is significantly higher in brain
tissues than in cell lines and adult neural stem cells. AD
pathogenic protein amyloid peptide led to a decrease of
global 5hmC in cultured cells. Our in vivo study also
found the level of 5hmC decreased in one specific brain
region, i.e., the hippocampus, but not other studied
brain regions of AD mice during the pathogenesis of
AD. Genome-wide profiling results indicated that the
distribution of 5hmC altered in distinct genomic regions,
especially in gene bodies. The differentially hydroxy-
methylated regions (DhMRs) identified in hippocampus
of aged D-Tg mice displayed high enrichment of mul-
tiple signaling pathways that are related to neuronal de-
velopment and neuronal function. Some AD-associated
genes showed altered hydroxymethylation. Our study
therefore uncovered new roles for 5hmC-mediated
epigenetic modification in neurologic disorders and re-
vealed a new layer of the pathogenic mechanism of AD.
Global and site-specific alterations of DNA methyla-
tion had been identified in AD [10, 14, 15, 43–45].
Epigenome-wide association with AD revealed the rela-
tionship between differential methylation of CpGs and
the expression of nearby genes, some of which are con-
nected to a known AD susceptibility network [11, 12].
Previous studies had inconsistently reported about the
Fig. 5 Identification and characterization of DhMRs in AD mouse model. a A representative IGV image shows the reduction of overall 5hmC in
aged DTg mice compared to WT mice and adult DTg mice. b-c Representative IGV images show the decrease of 5hmC in some genomic regions
of Ank1 and Cdh23. d 5hmC highly enriched in the gene body of APP gene in adult and aged DTg mice compared to WT mice. MACS software
default statistic test, p-value cutoff: 1X10−5
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alteration of DNA demethylation [38–41]. In our present
study, Aβ treatment led to a significant decrease in glo-
bal 5hmC level of different types of cells in vitro. The
significant alteration of demethyaltion was only observed
in hippocampus but not in cortex and cerebellum during
the ageing of AD model mice, suggesting the alteration
of demethylation is region specific, which might explain
the data contradiction between different studies. Consid-
ering the acquired Aβ deposition during the ageing of
AD model mice, these results indicated the increased Aβ
deposition decreased overall 5hmC level. Together with
previous studies, it supports the idea that dysregulation
of DNA demethylation is age- and region/loci specific,
indicating an interaction between amyloid accumulation
and DNA modification.
Previous studies have found 5hmC is highly enriched
in the neuronal system [19, 26], and the enrichment is
enhanced and displays dynamic features during postnatal
development and aging of the brain [20, 46], indicating
5hmC could be important for brain function. Subse-
quent studies did find that 5hmC-mediated epigenetic
modification is involved in multiple neurological disor-
ders, including autism spectrum disorders, Huntington’s
disease, and FXTAS [20, 25, 36, 37]. Moreover, the Rett
syndrome protein MeCP2 could bind to 5hmC, and its
dosage is negatively correlated with 5hmC level [20, 35].
Our present results revealed that the overall distribution
features of 5hmC in TSSs, TESs, and CpG islands did
not change, but the enrichment of 5hmC in gene bodies
was significantly decreased compared with age-matched
WT mice. Previous research found that the 5hmC level
in gene bodies is positively correlated with gene expres-
sion [20, 47]. Our results that the highly enrichment of
5hmC in the gene body of APP further supports this
concept. Considering no observable difference of 5hmC
in another overexpressed gene PSEN1, it suggests that
5hmC enrichment in gene body is one but all of mecha-
nisms to modulate gene expression. Further, our present
studies identified some DhMR-associated genes enriched
in multiple signaling pathways that are related to neur-
onal function and neurological disorders [20, 25, 36, 37].
These results suggest a potential mechanism to explain
how 5hmC-mediated epigenetic modification functions.
Our present studies also uncovered altered demethyla-
tion in some specific loci in aged D-Tg mice, and some
loci were related with the onset and progress of AD.
Interestingly, the loci with altered DNA demethylation
identified in our study were also found displaying altered
DNA methylation profile by two large-scale studies in
human [11, 12]. Although our present and these two
studies mainly provided the relevant evidence, all these
results suggest DNA methylation and demethylation
changes are involved in AD. Further experimental work
needs to be conducted to address the mechanism how
altered DNA methylation and demethylation affect the
onset and pathogenesis of AD.
Conclusion
Overall, our results indicate that not only is the global
level but also the distribution features of 5hmC altered
in AD model mice. Aβ treatment decreased 5hmC both
in vitro and in vivo. The acquisition of 5hmC in gene
bodies during postnatal development was significantly
inhibited in the hippocampus of AD model mice, al-
though the overall features in TSSs, TESs, and CpG
islands were unaffected. The DhMR-associated genes
identified in AD mice are specifically related to some
signaling pathways that play a role in neuronal function
and neurological disorders. Taken together, our present
results argue that 5hmC-mediated epigenetic modifica-
tion could have an important function in AD.
Methods
Animals
Twelve- and 67-week-old wild-type (WT) and APP/PS1
double transgenic littermate mice were used in this study
[48]. Mice were maintained at ambient temperature (22-
24 °C) on a 12:12 light/dark cycle with free access to food
and water. All animal procedures were performed accord-
ing to protocols approved by Emory University Institu-
tional Animal Care and Use Committee.
Genomic DNA isolation and 5hmC dot-blot
Genomic DNA was extracted as described previously [25].
Briefly, the dissected brain samples or cells were homoge-
nized in lysis buffer (5 mM EDTA, 0.2 % SDS, 200 mM
NaCl in 100 mM Tris–HCl, pH 8.5) supplemented with
proteinase K, and samples were kept at 56 °C overnight.
The second day, an equal volume of phenol:chloroform:i-
soamyl alcohol (25:24:1, P-3803, Sigma) was added, mixed
completely, and centrifuged at 14,000 rpm for 10 min. An
equal volume of isopropanol was added to the supernatant
to precipitate DNA, which was dissolved with 10 mM
Tris–HCl (pH 8.0).
5hmC dot-blot was performed as before [20]. In brief,
genomic DNA was spotted on an Amersham Hybond-N+
membrane (GE Healthcare), followed by baking at 80 °C
for 30 min. The membrane was incubated with polyclonal
5hmC antibody (Active Motif, #39769) overnight at 4 °C.
The second day, a horseradish-peroxidase-conjugated sec-
ondary antibody against rabbit was used to probe.
Cell culture and Aβ treatment
HEK293 cells were maintained in DMEM supplemented
with 10 % fetal bovine serum, 2 mM glutamine, and 100
U penicillin–streptomycin at 37 °C in a humidified incu-
bator containing 5 % CO2. Cells were treated with Aβ
peptide (Sigma, A9810) at a concentration of 0.5, 0.75,
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or 1 μM for 48 h, respectively. The isolation, culture and
determination of adult neural stem cells were performed
as described previously [49].
Immunocytochemistry
The cultured aNSCs were fixed with 4 % parafromalde-
hyde for 30 min at room temperature, followed by wash-
ing with cold PBS for 15 min. The cells were blocked with
3 % goat serum and 0.1 % TritonX-100 in PBS for 1 h at
room temperature, followed by the incubation with pri-
mary antibodies at 4 °C overnight. The second day, the
cells were incubated with secondary antibodies after
washed with PBS for 30 min. The images were taken with
a Zeiss confocal microscope. Primary antibodies: Rabbit
SOX2 (Millipore, Ab5603), Mouse Nestin (BD, #556309).
Secondary antibodies: goat anti Rabbit 488 (Invitrogen,
A11008), goat anti Mouse 568 (Invitrogen, A11004).
5hmC-specific enrichment and high-throughput
sequencing
Chemical labeling-based 5hmC enrichment was described
previously [26]. Briefly, DNA was sonicated to 100–500 bp,
and then mixed with 100 μl solution containing 50 mM
HEPES buffer (pH 7.9), 25 mM MgCl2, 250 μM UDP-6-
N3-Glu, and 2.25 μM β-glucosyltransferase for 1 h at 37 °C.
DNA substrates were purified via Qiagen DNA purification
kit. 150 μM dibenzocyclooctyne modified biotin was then
added to the purified DNA, and the labeling reaction was
performed for 2 h at 37 °C. The biotin-labeled DNA was
enriched by Streptavidin-coupled Dynabeads (Dynabeads®
MyOne™ Streptavidin T1, Life Technologies) and purified.
5hmC libraries were generated with 25 ng input or
5hmC-captured DNA according to the manufacturer’s
protocol (NEBNext ChIP-Seq Library Prep Reagent
Set for Illumina). DNA fragments between 150 and
300 bp were gel-purified after the adapter ligation
step. An Agilent 2100 BioAnalyzer was used to quan-
tify the amplified DNA. 20 pM diluted libraries were
eventually used for sequencing.
Sequence alignment and mapped reads annotation
FASTQ sequence files were aligned to mouse NCBI37v1/
mm9 references using Bowtie 0.12.9. Each unique mapped
read with no more than two mismatches in the first 25 bp
was concatenated to achieve combined wild-type and
APP/PS1 mice 5hmC sequence. Association of mapped
reads with genomic features was performed by overlapping
reads files with known genomic features obtained from
UCSC Tables for NCBI37v1/mm9. Unique 5hmC mapped
reads were plotted to various genomic regions using an R
program package termed ngsplot (https://code.google.-
com/p/ngsplot/).
DhMR identification, annotation, and motif analysis
Model-based Analysis of ChIP-Seq (MACS) software [42]
was adopted to identify DhMRs between WT and DTg
mice by directly comparing one to the other, rather than
comparing to the input. The effective genome size =
1.87 × 109, tag size = 38, bandwidth = 200, P-value
cutoff = 1.00 × 10−5. Identified WT and DTg-specific
DhMRs were annotated to various genomic regions and
associated genes by HOMER software [50]. DhMR-
associated genes were extracted, and enrichment
analysis was performed with WebGestalt (http://bioin-
fo.vanderbilt.edu/webgestalt/) [51].
Statistics
Data are expressed as the mean ± standard error of the
mean (s. e. m.), and statistical significance of differences
between different groups was assessed using the t-test or
ANOVA assay.
Additional files
Additional file 1: Figure S1. A representative image of methylene blue
staining showing the equal spotting of DNA in the membrane. Figure S2
5hmC chromosome-wide densities showing the distribution profiling on
chromosomes. A depletion is observed on chr-X relative to autosomes.
Figure S3 Representative IGV images show the decrease of 5hmC in some
genomic regions of genes identified in two AD EWAS datasets.
(PPTX 2495 kb)
Additional file 2: Table S1. Reads info. (XLSX 10 kb)
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